High expression of VTA1 is an adverse prognostic factor in lung adenocarcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.VTA1 is highly expressed in lung adenocarcinoma (LUAD), a non-small cell lung cancer type. High VTA1 expression indicates a poor prognosis and serves as a potential biomarker for adverse outcomes in LUAD patients.
Area Of Science
- Oncology
- Molecular Biology
- Genomics
Background
- Lung adenocarcinoma (LUAD) is a prevalent non-small cell lung cancer subtype.
- Identifying reliable biomarkers for LUAD progression is a critical clinical challenge.
- VTA1's role in LUAD has been underexplored despite its association with other cancers.
Purpose Of The Study
- To investigate the expression patterns of VTA1 in LUAD.
- To analyze the correlation between VTA1 expression and clinical outcomes in LUAD patients.
- To explore the molecular mechanisms and pathways associated with VTA1 in LUAD.
Main Methods
- Utilized RNA sequencing data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) projects.
- Performed differential gene expression (DEG) analysis, Gene Ontology (GO)/Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, Gene Set Enrichment Analysis (GSEA), and protein-protein interaction (PPI) network analysis.
- Assessed clinical significance using Kaplan-Meier survival analysis, Cox regression, and prognostic nomogram models.
Main Results
- VTA1 was significantly upregulated in LUAD tissues compared to normal samples.
- High VTA1 expression correlated with advanced T, N, M stages, pathological stages, and residual tumor status.
- High VTA1 expression was an independent prognostic factor for poor survival in LUAD patients and associated with 4232 differentially expressed genes.
Conclusions
- VTA1 overexpression is a potential biomarker for adverse prognosis in lung adenocarcinoma.
- The identified DEGs and pathways offer insights into LUAD tumorigenesis and progression.
- Further research into VTA1's role could lead to novel therapeutic strategies for LUAD.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...